How To Inject Wegovy: Clinical Preparation Guide

Last reviewed: May 27, 2026

Last updated: May 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Wegovy injection technique involves subcutaneous administration using a pre-filled pen, with dose escalation beginning at 0.25 mg weekly and titrating upward over 16 weeks. Proper technique—including site rotation, needle depth, and injection timing—reduces complications and supports consistent therapeutic response.

Before mastering injection mechanics, clinical readiness matters equally. Understanding your metabolic profile, GLP-1 receptor sensitivity patterns, and individual risk factors through genetic screening may help provide context for why certain dose progressions or formulations might suit your situation better than others.

Understanding the Injection Mechanism and Device Setup

Wegovy arrives as a pre-filled, multi-dose injection pen containing semaglutide solution. The pen uses a 31-gauge needle and delivers 0.5 mL per injection across dose strengths. Familiarizing yourself with the pen mechanics—priming, dose selection, and needle attachment—before your first injection reduces anxiety and administration errors.

Device setup requires removing the pen from refrigeration 30 minutes before use, allowing the solution to reach room temperature. Inspect the liquid for clarity; cloudiness or particulates indicate the pen should not be used. Attach a new needle, prime the device by dialing to 2 mg and pressing the injection button until liquid appears at the needle tip, then dial your prescribed dose.

Dose Progression Protocol and Metabolic Readiness

Wegovy follows a 16-week titration schedule starting at 0.25 mg weekly, increasing every 4 weeks. Standard progression moves through 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg maintenance doses. Some providers adjust pace based on tolerability; slower escalation may suit individuals with sensitivity to gastrointestinal side effects or metabolic adaptations.

Genetic variants in GLP-1 receptor and GIPR pathways can influence how individuals respond during titration. Understanding your genetic profile through Precision Peptide testing may help provide context for why your provider might recommend a personalized pace rather than standard escalation.

Week Range	Dose (mg)	Injection Frequency	Clinical Considerations
Weeks 1–4	0.25	Once weekly	Baseline tolerability assessment; GI side effects common
Weeks 5–8	0.5	Once weekly	Efficacy plateau often observed; appetite suppression increases
Weeks 9–12	1.0	Once weekly	Risk of rapid weight loss; monitor for dehydration
Weeks 13–16	1.7–2.4	Once weekly	Maintenance phase; individual response variation highest

Injection Site Selection and Anatomical Rotation

Wegovy is administered subcutaneously in the abdomen, thigh, or upper arm. Rotating sites reduces lipodystrophy—localized fat loss or thickening—and ensures consistent absorption. Abdomen injections (2 inches from navel) show fastest absorption; thigh and arm sites have slightly delayed pharmacokinetics but equal efficacy over time.

Maintain at least 1 inch between injection sites and avoid areas with active bruising, scars, or inflammation. Document your injection sites weekly using a simple chart to prevent repeated needle trauma. Consistent rotation supports stable drug levels and reduces tissue complications over months of therapy.

Pre-Injection Clinical Readiness and Safety Eligibility

Before your first injection, confirm contraindications are absent: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis, severe renal impairment, or diabetic retinopathy requiring urgent treatment. A qualified provider should review your complete medication list, as semaglutide interacts with sulfonylureas and insulin agents.

Biomarker assessment—including fasting glucose, lipid panels, and inflammatory markers—provides baseline context for tracking medication impact. Genetic screening through Precision Peptide testing reveals predispositions in GLP-1 and GIPR pathways, which should be interpreted with your provider to support informed dosing and personalization decisions, though genetics alone do not predict exact individual response.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test examines key variants in GLP-1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) pathways. These genetic predispositions may help provide context for individual differences in appetite suppression, weight loss patterns, and metabolic response during GLP-1 therapy, supporting more informed conversations with your healthcare provider.

The genetic test does not predict exact medication response or guarantee outcomes; rather, it reveals predispositions that can inform personalized treatment planning. Understanding your genetic profile alongside clinical biomarkers and dose tolerance allows your provider to tailor injection schedules, formulation choices, and escalation pace to your unique physiology.

If you choose to explore compounded semaglutide or tirzepatide options through PlexusDx, pairing genetic insights with provider-guided injection training ensures you maximize safety and efficacy. Genetic and biomarker data should always be interpreted by a qualified healthcare provider in the context of your full medical history.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the correct needle angle for a Wegovy injection?

Insert the needle at a 90-degree angle (perpendicular to skin) into subcutaneous tissue, approximately 0.5 inches deep. Hold the pen steady for 3 seconds after injection to ensure complete medication delivery and minimize leakage.

Can I skip a Wegovy dose if I miss my injection day?

If you miss an injection within 2 days of your scheduled time, administer it as soon as possible. If more than 2 days have passed, skip that dose and resume your normal schedule the following week. Never double-dose to compensate for a missed injection.

How does the Precision Peptide Genetic Test relate to Wegovy effectiveness?

The test examines GLP-1 receptor and related metabolic variants that may influence appetite suppression and weight loss response patterns. Results should be interpreted with your provider to support personalized dosing conversations, though genetics do not predict exact individual outcomes.

What are the most common injection site complications?

Lipohypertrophy (localized fat thickening) and lipoatrophy (fat loss) occur with repeated injections in the same area. Proper site rotation every week and avoiding previously bruised or scarred tissue minimize these risks significantly.

Does PlexusDx offer compounded semaglutide as an alternative to Wegovy?

Yes. PlexusDx offers compounded semaglutide injection starting at $149 monthly through licensed 503A pharmacies. Compounded formulations follow similar injection protocols and should be administered under qualified provider supervision.

How To Inject Wegovy: Clinical Preparation and Personalized Readiness